Business · 1 sources covering this

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

CNBCLean R·12h ago
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.
Read at CNBC →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/a19f7a95174857a4463ec277c71b18404449fea4"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China"></iframe>

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

How 1 sources are covering this

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

More from Business

Asia-Pacific markets set to open mixed as Trump signals no rush on Iran agreement

The daughter of Thailand's beer billionaire says she never doubted women belonged at the top

Caribbean hot sauce producers warn of shortages and higher prices

Japanese bond yields are the highest in 40 years. The budget and a 'red flag' from PM Takaichi have markets nervous

Reader

Trust & legal

Across the network